%0 Journal Article
%T A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
%A Agnese Latorre
%A Alain Gelibter
%A Alessandra Cassano
%A Andrea Botticelli
%A Angela Vaccaro
%A Angelo Fedele Scinto
%A Antonio Giordano
%A Carlo Garufi
%A Clara Natoli
%A Claudia Omarini
%A Daniele Santini
%A Domenico Corsi
%A Domenico Sergi
%A Emanuela Magnolfi
%A Emilio Bria
%A Enzo Veltri
%A Ernesto Rossi
%A Francesco Giotta
%A Gennaro Ciliberto
%A Giacomo Barchiesi
%A Giancarlo Paoletti
%A Giuseppe Sanguineti
%A Giuseppe Tonini
%A Ida Paris
%A Isabella Sperduti
%A Jennifer Foglietta
%A Laura Iezzi
%A Laura Pizzuti
%A Loretta D¡¯Onofrio
%A Luca Moscetti
%A Lucia Mentuccia
%A Luciano Mariani
%A Luigi Di Lauro
%A Luisa Carbognin
%A Maddalena Barba
%A Marcello Maugeri-Sacc¨¤
%A Marco Mazzotta
%A Maria Agnese Fabbri
%A Paolo Marchetti
%A Patrizia Vici
%A Riccardo Samaritani
%A Roberta Sarmiento
%A Rosanna Mirabelli
%A Ruggero De Maria
%A Sandro Barni
%A Silverio Tomao
%A Teresa Gamucci
%A Valentina Magri
%A Vincenzo Graziano
%J Archive of "Cancer Biology & Therapy".
%D 2019
%R 10.1080/15384047.2018.1523095
%X We carried out a retrospective observational study of 264 HER2-positive advanced breast cancer (ABC) patients to explore the efficacy of first-line treatment with pertuzumab/trastuzumab/taxane in real-world setting. Survival data were analyzed by Kaplan Meier curves and log rank test
%K metastatic breast cancer
%K pertuzumab
%K trastuzumab
%K maintenance
%K HER2
%K first-line treatment
%K endocrine therapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343690/